Bruce Springsteen & The E-Street Band Tribute for GoFAR – Joe Castellani & The Adriatic Devils

Senigallia Foro Annonario - 13 agosto 2016 ore 22

Data by 0 comment

Bruce Springsteen & The E-Street  Band Tribute

Salva la data! GoFAR – Incontro informativo

Torino Ospedale San Luigi - 28 maggio 2016 - ore 12,00

Data by 0 comment

Early and longitudinal assessment of neurodegeneration in the brain and spinal cord in Friedreich’s ataxia (II year)

Pierre-Gilles Henry Ph.D, Christophe Lenglet Ph.D

Data by 0 comment

gofar1-logo fara ataxiauk2-logo

Progetto: Early and longitudinal assessment of neurodegeneration in the brain and spinal cord in Friedreich’s ataxia (II year)

Principal Investigators: Pierre-Gilles Henry, Ph.D, Christophe Lenglet, Ph.D – Center for Magnetic Resonance Research, Department of Radiology,University of Minnesota Medical School, Minneapolis US

We propose to assess the sensitivity of candidate biomarkers forFriedreich’s ataxia in patients, using Magnetic Resonance Imaging (MRI) techniques.Sensitive early-stage biomarkers of the disease are currently lacking in Friedreich’s Ataxia (FRDA).Such biomarkers would constitute an invaluable tool for monitoring disease progression in prospective therapeutic trials.In this project, we propose to use both Magnetic Resonance Spectroscopy (MRS) and diffusionMagnetic Resonance Imaging (diffusion MRI). MRS allows non-invasive measurement of a“neurochemical profile” of 10-15 metabolites, and has the potential to reveal biochemical alterations in the nervous system before irreversible tissue damage. Diffusion MRI, in combination with advanced white matter fiber orientation mapping and tractography algorithms, provides unprecedented information about the integrity of the cerebral, cerebellar and spinal axonal wiring.Preliminary data obtained in our center in the past year shows significant differences in both MRS and diffusion MRI data between patients and controls. In this project based on our preliminary results, we propose to focus on a subset of the data already acquired and investigate year-to-year temporal changes in Friedreich’s ataxia.We hope to identify sensitive biomarkers of the disease in the central nervous system of patients with Friedreich’s ataxia at an early stage, and gain better insights into their temporal evolution. These aims could ultimately provide novel and unique tools for the quantitativeassessment of treatment efficacy in prospective therapeutic trials.

Finanziamento: 150,000 $ (1anno da 1 Settembre 2015) Co-finanziato da FARA e Ataxia UK

Investigation of mitochondrial function and novel therapies in Friedreich’s ataxia mouse models (II year)

Dr. Paola Giunti, Dr. Andrey Abramov

Data by 0 comment

gofar1-logo fara

Progetto: Investigation of mitochondrial function and novel therapies in Friedreich’s ataxia mouse models (II years)

Principal Investigator: Dr. Paola Giunti, Co-PI Andrey Abramov Department of Molecular Neuroscience Institute of Neurology, UCL, London

We propose to study the mitochondrial pathophysiology in FRDA using mouse models (YG8R and KIKO), and the pharmacological effects of Nrf2 inducers and D-PUFAs compounds on the mitochondrial function in models, looking at different cell types variably involved in the disease, such as neurons and glia of the cerebellum and kidney fibroblast cells.

The methodologies chosen to achieve our goals include: cell biology, functional microscopy, fluorescence imaging techniques, and oxygen consumption measurements. Experiments will be conducted initially on primary cultures of cerebellar granular cells, co-cultures of neurons and glia, freshly isolated a kidney fibroblast cells. These cell culture preparations are currently used in our lab for other projects. The assays will include pre-clinical studies of two different types of drugs that will tackle potential therapeutic targets to envisage novel pharmaceutical trials for FRDA patients. The first type of compounds are Nrf2 inducers, that will trigger the antioxidant pathway of Nrf2, which has been found to be involved in FRDA (Shan et al,. 2013), and will also provide mitochondrial respiration substrates, helping the mitochondrial bioenergetics (Homstrom et al., 2013; Luthmann et al., 2013). The second type of compounds, D-PUFAs, will protect the cells from lipid peroxidation, which is relevant in FRDA mitochondrial function and, more importantly, our preliminary data has shown that FRDA mouse model cerebellar granule cells undergo dramatic increases in lipid peroxidation.

Finanziamento: 77,586 GBP ( 1anno da 21 Agosto 2015) Co-finanziato da FARA

 

 

Il Sole 24 Ore – Speciale Onlus – Realtà Eccellenti

Sfida all'Atassia di Friedreich con passione e professionalità.

Data by 0 comment

sole 24 ore

International Ataxia Research Conference 2015

Abstract & Poster presentations

Data by 0 comment
International-Ataxia-Research-Conference-2015-Abstracts

Apri International Ataxia Research Conference 2015

Apri Poster presentation

Apri Poster presentation

New Mouse Models of Friedreich’s Ataxia

Dr.Cathleen M Lutz

Data by 0 comment

gofar1-logo fara

Progetto: New Mouse Models of Friedreich’s Ataxia

Principal Investigator: Dr.Cathleen M Lutz, PhD- Director of Rare and Orphan Disease Center, Director of Mouse Repository – Jackson Laboratory, USA.

Il progetto supporta l’ingegnerizzazione presso il Laboratorio Jackson (JAX)  di due nuovi modelli di atassia di Friedreich (FRDA), un  BAC transgenico con una lunga ripetizione GAA  e un modello  di topo  Knock-in  con ripetizioni GAA nel locus della Fratassina. Il finanziamento ricevuto sarà utilizzato per creare tali modelli sulla base delle osservazioni cliniche di riferimento relative al peso e alla sopravvivenza e con un fenotipo manifesto.

JAX ha collaborato con la comunità FRDA sin dal 2007 importando e standarizzando gli esistenti modelli di topo FRDA.  In uno studio compartivo longitudinale è stato determinato che tutti  i modelli esistenti, pur con vari livelli di espressione della proteina Fratassina,  presentano un fenotipo neurologico (per esempio andatura)  molto subdolo che inizia a manifestarsi solo intorno ai 9-12 mesi di vita dell’animale. Mentre questi modelli sono adatti ad essere usati in studi preclinici atti a testare la sovra –regolazione della espressione del gene della Fratassina  e a misurare la proteina, essi falliscono nel  rilevamento di importanti misure di efficacia neurologica a breve tempo.

Nel Maggio del 2014 GoFAR e FARA  hanno organizzato un meeting a Filadelfia per superare l’esistente ostacolo della carenza di un modello FRDA adeguato a fornire informazioni in tempi brevi relative all’efficacia di eventuali trattamenti atti a curare la FRDA. E’stato deciso che tale ingegnerizzazione sarebbe avvenuta allo JAX per assicurare la rapida caratterizzazione e distribuzione  di questi nuovi modelli FRDA.

Finanziamento: 85.440 $ (Agosto 2014-Luglio 2015) Co-finanziato da FARA